Introduction {#jcmm13079-sec-0001}
============

AD, the most common type of dementia in ageing population, is characterized by progressive cognitive impairment and memory loss. Extracellular amyloid plaques and intracellular neurofibrillary tangles are two core pathological hallmarks of AD [1](#jcmm13079-bib-0001){ref-type="ref"}. Although the processes of AD could be triggered by many environmental factors, previous studies also suggested that genetic polymorphisms play an important role in AD, among which mutations in amyloid precursor protein (APP), presenilin‐1 (PSEN1), presenilin‐2 (PSEN2) and apolipoprotein E (APOE) have been proved to be associated with AD risk [2](#jcmm13079-bib-0002){ref-type="ref"}. However, AD is such a complex disorder that the genes mentioned above cannot explain the overall genetic susceptibility, and additional genetic risk factors may be involved in the development of AD.

STH, an intronless gene, was first discovered between exons 9 and 10 of the human microtubule‐associated protein tau (MAPT) gene on chromosome 17q21.1 and rediscovered in MAPT 5′ intron 11 [3](#jcmm13079-bib-0003){ref-type="ref"}, [4](#jcmm13079-bib-0004){ref-type="ref"}. It encodes a 128‐amino acid protein with no clear homologues [3](#jcmm13079-bib-0003){ref-type="ref"}. This region is functionally critical for alternative splicing of exon 10, and the tissue expression of STH is similar to tau, which indicates STH gene a possible role in AD and other neurodegenerative disorders. A single‐nucleotide polymorphism \[A→G\] (rs62063857) in human STH gene results in an amino acid change from glutamine (Q) residue 7 to arginine (R). Conrad *et al*. (2002) first reported that the RR genotype and R allele were associated with a higher risk for late‐onset Alzheimer\'s disease (LOAD) independently from APOE‐4 genotype \[odds ratio (OR), 11.92 for genotype; 3.11 for allele\] [3](#jcmm13079-bib-0003){ref-type="ref"}. If this initial report was convincing, the Q7R polymorphism would become the second most important genetic susceptibility factor for AD. Subsequently, a large amount of studies were performed to confirm the important finding, whereas results were conflicting.

The issue has been discussed in one meta‐analysis published in 2004 [5](#jcmm13079-bib-0005){ref-type="ref"}. However, the meta‐analysis failed to include all eligible studies--a study by Pepłon′ska *et al*., Oliveira *et al.,* and Clark *et al.,* in 2003 [6](#jcmm13079-bib-0006){ref-type="ref"}, [7](#jcmm13079-bib-0007){ref-type="ref"}, [8](#jcmm13079-bib-0008){ref-type="ref"}. Additionally, a further eight papers focusing on the relationship between the Q7R polymorphism and AD susceptibility have emerged with inconsistent findings as the meta‐analysis was conducted [9](#jcmm13079-bib-0009){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [11](#jcmm13079-bib-0011){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [13](#jcmm13079-bib-0013){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}, [16](#jcmm13079-bib-0016){ref-type="ref"}. Therefore, we performed this meta‐analysis of the existing studies to determine whether there is an association between STH Q7R polymorphism and AD risk.

Materials and methods {#jcmm13079-sec-0003}
=====================

Literature search {#jcmm13079-sec-0004}
-----------------

This meta‐analysis was performed according to the methodology advocated by the Meta‐analysis of Observational Studies in Epidemiology (MOOSE) guideline [17](#jcmm13079-bib-0017){ref-type="ref"}. To identify all publications relevant to the association between STH Q7R polymorphism and AD, two investigators independently performed a systematic electronic literature search in the PubMed, Embase, Cochrane Library and Web of Science with the following terms: ('Alzheimer\'s disease' or 'AD') and ('saitohin' or 'STH') and ('polymorphism' or 'mutation' or 'variant'). We also searched for additional publications in personal reference lists from original research articles and review articles. The articles selected were restricted to studies in humans and written in English, but without restriction on time period, sample size or population of the published paper. The last literature search was updated to 31 August 2016.

Literature inclusion {#jcmm13079-sec-0005}
--------------------

All studies eligible for the meta‐analysis had to meet the following inclusion criteria: (*i*) studies designed as case--control type; (*ii*) writing in English; (*iii*) reporting the association between STH Q7R polymorphism and AD and (*iv*) providing detailed genotype counts essential for the calculation of ORs and 95% confidence intervals (CIs). Exclusion criteria were as follows: (*i*) study design based on family or sibling pairs; (*ii*) case reports, editorials, reviews and meta‐analyses and (*iii*) insufficient information for data extraction. Additionally, if there was more than one publication from the same population, only the most recent or comprehensive study was included in the meta‐analysis.

Data extraction {#jcmm13079-sec-0006}
---------------

The following information was extracted and tabulated by two independent reviewers: the first author\'s name, year of publication, country of origin, ethnicity, total number of cases and controls, mean age of cases and controls, gender proportion of cases and controls, diagnostic criteria of AD, time of AD onset, genotype and allele distributions of cases and controls, and *P* value for the control in the Hardy--Weinberg equilibrium (HWE). With regard to different results, a third reviewer participated in the discussion to solve the discrepancies.

Quality assessment {#jcmm13079-sec-0007}
------------------

The quality of the studies included in the meta‐analysis was evaluated by a set of predetermined criteria by Thakkinstian *et al*. (2005), which contains the representativeness of cases, representativeness of controls, ascertainment of cases, control selection, genotyping examination, HWE in controls and total sample size [18](#jcmm13079-bib-0018){ref-type="ref"}. The criteria have been previously structured as a 22‐item list with scores ranging from 0 to 15 and widely used in various meta‐analyses [19](#jcmm13079-bib-0019){ref-type="ref"}, [20](#jcmm13079-bib-0020){ref-type="ref"}. As in previous meta‐analyses, a study score ≥10 was considered to be high quality, while score \<10 was considered to be low quality.

Statistical analysis {#jcmm13079-sec-0008}
--------------------

Pooled ORs and 95% CIs were calculated to assess the association between STH Q7R polymorphism and the risk of AD under different comparison models, including allele model (R *versus* Q), dominant model (RR+QR *versus* QQ), recessive model (RR *versus* QQ+QR), homozygous model (RR *versus* QQ) and heterozygous model (QR *versus* QQ). Subgroup analyses were also performed to evaluate the effect of Q7R polymorphism on AD susceptibility according to the differences in time of AD onset (EOAD or LOAD) and quality score of included articles (high quality or low quality), respectively. Statistical heterogeneity between studies was tested by *I* ^2^ statistics and Q test. With the absence of heterogeneity (*I* ^2 ^\< 50% or *P* ~Q~ * *≥ 0.1), the pooled ORs were merged by the fixed‐effects model (the Mantel--Haenszel method), while with the presence of heterogeneity (*I* ^2 ^≥ 50% or *P* ~Q~ \< 0.1), the random‐effects model (the Der Simonian and Laird method) was used. If heterogeneity was detected, Galbraith plot analyses were conducted to find out whether there were outliers that could be the potential sources of heterogeneity. The HWE was assessed by chi‐squared test using genotype data from controls. A sensitivity analysis for the overall effect was conducted by sequential removal of the four studies in which the HWE in the control group was not reported, as they may generate possible bias [9](#jcmm13079-bib-0009){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}. Publication bias was investigated with funnel plot and Egger\'s test (*P *\< 0.05 indicated a significant publication bias). All statistical analyses were performed with STATA Version 12.0 (College Station, TX, USA).

Results {#jcmm13079-sec-0009}
=======

Study characteristics {#jcmm13079-sec-0010}
---------------------

A total of 126 articles were identified in the literature search of PubMed, Embase, Cochrane Library and Web of Science using different combinations of keywords (Fig. [1](#jcmm13079-fig-0001){ref-type="fig"}). After a careful review, 19 case--control studies from 17 articles with 4387 cases and 3972 controls were included in our meta‐analysis to determine the association between STH Q7R polymorphism and AD [3](#jcmm13079-bib-0003){ref-type="ref"}, [5](#jcmm13079-bib-0005){ref-type="ref"}, [6](#jcmm13079-bib-0006){ref-type="ref"}, [7](#jcmm13079-bib-0007){ref-type="ref"}, [8](#jcmm13079-bib-0008){ref-type="ref"}, [9](#jcmm13079-bib-0009){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [11](#jcmm13079-bib-0011){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [13](#jcmm13079-bib-0013){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}, [16](#jcmm13079-bib-0016){ref-type="ref"}, [21](#jcmm13079-bib-0021){ref-type="ref"}, [22](#jcmm13079-bib-0022){ref-type="ref"}, [23](#jcmm13079-bib-0023){ref-type="ref"}, [24](#jcmm13079-bib-0024){ref-type="ref"} (Table [1](#jcmm13079-tbl-0001){ref-type="table-wrap"}). Of the selected studies, 15 studies included populations of caucasian [3](#jcmm13079-bib-0003){ref-type="ref"}, [5](#jcmm13079-bib-0005){ref-type="ref"}, [6](#jcmm13079-bib-0006){ref-type="ref"}, [7](#jcmm13079-bib-0007){ref-type="ref"}, [8](#jcmm13079-bib-0008){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [11](#jcmm13079-bib-0011){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [13](#jcmm13079-bib-0013){ref-type="ref"}, [16](#jcmm13079-bib-0016){ref-type="ref"}, [21](#jcmm13079-bib-0021){ref-type="ref"}, [22](#jcmm13079-bib-0022){ref-type="ref"}, [23](#jcmm13079-bib-0023){ref-type="ref"}, [24](#jcmm13079-bib-0024){ref-type="ref"}, three of Asian [9](#jcmm13079-bib-0009){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"} and one of African [8](#jcmm13079-bib-0008){ref-type="ref"}. The diagnostic criteria of AD for 10 studies were the National Institute of Neurological Disorders and Stroke/Alzheimer Diseases and Related Disorders Association criteria (NINCDS/ADRDA criteria) [6](#jcmm13079-bib-0006){ref-type="ref"}, [9](#jcmm13079-bib-0009){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [13](#jcmm13079-bib-0013){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [16](#jcmm13079-bib-0016){ref-type="ref"}, [21](#jcmm13079-bib-0021){ref-type="ref"}, [23](#jcmm13079-bib-0023){ref-type="ref"}, [24](#jcmm13079-bib-0024){ref-type="ref"}, four studies were NINCDS/ADRDA criteria accompanied by the Consortium to Establish a Registry for Alzheimer\'s Disease (CERAD) or the third/fourth Diagnostic and Statistical Manual of Mental Disorders criteria (DSM‐III‐R/DSM‐IV criteria) [8](#jcmm13079-bib-0008){ref-type="ref"}, [11](#jcmm13079-bib-0011){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}, four studies were autopsy confirmed [3](#jcmm13079-bib-0003){ref-type="ref"}, [5](#jcmm13079-bib-0005){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [22](#jcmm13079-bib-0022){ref-type="ref"} and one study was CERAD and National Institute on Aging and the Reagan Institute (NIA‐Reagan) criteria [7](#jcmm13079-bib-0007){ref-type="ref"}. Six studies only included late‐onset AD subjects [8](#jcmm13079-bib-0008){ref-type="ref"}, [13](#jcmm13079-bib-0013){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}, [22](#jcmm13079-bib-0022){ref-type="ref"}, and the others included both early‐onset and late‐onset subjects [3](#jcmm13079-bib-0003){ref-type="ref"}, [5](#jcmm13079-bib-0005){ref-type="ref"}, [6](#jcmm13079-bib-0006){ref-type="ref"}, [7](#jcmm13079-bib-0007){ref-type="ref"}, [9](#jcmm13079-bib-0009){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [11](#jcmm13079-bib-0011){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [16](#jcmm13079-bib-0016){ref-type="ref"}, [21](#jcmm13079-bib-0021){ref-type="ref"}, [23](#jcmm13079-bib-0023){ref-type="ref"}, [24](#jcmm13079-bib-0024){ref-type="ref"}, among which AD in three studies was stratified into two age groups [6](#jcmm13079-bib-0006){ref-type="ref"}, [21](#jcmm13079-bib-0021){ref-type="ref"}, [24](#jcmm13079-bib-0024){ref-type="ref"}. All of the studies included met the quality criteria with scores ranging from 5 to 12; six studies were considered as high quality [7](#jcmm13079-bib-0007){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [13](#jcmm13079-bib-0013){ref-type="ref"}, [22](#jcmm13079-bib-0022){ref-type="ref"}, [23](#jcmm13079-bib-0023){ref-type="ref"}, [24](#jcmm13079-bib-0024){ref-type="ref"}, and 13 were low quality [3](#jcmm13079-bib-0003){ref-type="ref"}, [5](#jcmm13079-bib-0005){ref-type="ref"}, [6](#jcmm13079-bib-0006){ref-type="ref"}, [8](#jcmm13079-bib-0008){ref-type="ref"}, [9](#jcmm13079-bib-0009){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [11](#jcmm13079-bib-0011){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}, [16](#jcmm13079-bib-0016){ref-type="ref"}, [21](#jcmm13079-bib-0021){ref-type="ref"}. The genotype distributions of the controls in 15 studies were consistent with HWE (*P *\> 0.05) [3](#jcmm13079-bib-0003){ref-type="ref"}, [5](#jcmm13079-bib-0005){ref-type="ref"}, [8](#jcmm13079-bib-0008){ref-type="ref"}, [10](#jcmm13079-bib-0010){ref-type="ref"}, [11](#jcmm13079-bib-0011){ref-type="ref"}, [13](#jcmm13079-bib-0013){ref-type="ref"}, [16](#jcmm13079-bib-0016){ref-type="ref"}, [21](#jcmm13079-bib-0021){ref-type="ref"}, [22](#jcmm13079-bib-0022){ref-type="ref"}, [23](#jcmm13079-bib-0023){ref-type="ref"}, [24](#jcmm13079-bib-0024){ref-type="ref"}, and the others were not reported [9](#jcmm13079-bib-0009){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}. Detailed characteristics of the studies included in this meta‐analysis are presented in Table [1](#jcmm13079-tbl-0001){ref-type="table-wrap"}. The distributions of genotypes and alleles in individual study are shown in Table [2](#jcmm13079-tbl-0002){ref-type="table-wrap"}.

![Flowchart of literature search.](JCMM-21-1448-g001){#jcmm13079-fig-0001}

###### 

Study characteristics from included studies in the meta‐analysis

  First author   Year   Country              Ethnicity   Case   Control   Diagnostic criteria of AD   Time of AD onset   QS                                                     
  -------------- ------ -------------------- ----------- ------ --------- --------------------------- ------------------ ----- ------- ------- ------------------------ ------- ----
  Conrad         2002   USA                  Caucasian   51     80.51     --                          --                 30    78.83   --      Autopsy‐confirmed        Mixed   7
  Verpillat      2002   France               Caucasian   499    --        63.8                        38%                402   66.6    48%     NINCDS‐ADRDA             Mixed   9
  Cook           2002   British              Caucasian   203    81.4      \>65                        34.5%              309   82.1    41.1%   Autopsy‐confirmed        LOAD    12
  Streffer       2003   Swiss, Greek         Caucasian   225    --        71.61                       --                 144   70.0    --      NINCDS‐ADRDA             Mixed   11
  Pepłon′ska     2003   Polish               Caucasian   100    76.4      71.5                        36%                100   71.2    21%     NINCDS‐ADRDA             Mixed   9
  Oliveira       2003   USA                  Caucasian   903    --        --                          --                 320   --      --      CERAD NIA‐Reagan         Mixed   11
  Clark‐1        2003   Whites, Hispanics    Caucasian   135    81.6      --                          22.5               340   75.7    35.8    NINCDS‐ADRDA DSM‐III‐R   LOAD    9
  Clark‐2        2003   African‐Americans    African     65                                                              118                   NINCDS‐ADRDA DSM‐III‐R   LOAD    9
  Combarros      2003   Spain                Caucasian   315    75.6      71.9                        30%                307   80.5    28%     NINCDS‐ADRDA             Mixed   10
  Tanahashi      2004   Japanese             Asian       15     --        --                          --                 15    --      --      NINCDS‐ADRDA             Mixed   6
  Seripa‐1       2004   USA                  Caucasian   117    80.89     71.65                       45.3%              99    83.75   46.5%   Autopsy‐confirmed (P)    Mixed   10
  Seripa‐2       2004   Italian              Caucasian   130    69.80     65.91                       42.3%              633   36.76   48.2%   NINCDS‐ADRDA             Mixed   9
  Conrad         2004   Germany              Caucasian   155    80.9      --                          --                 41    76.1    --      Autopsy‐confirmed        Mixed   7
  Johansson      2005   Sweden               Caucasian   398    77        73                          41.7%              186   72      43.5%   NINCDS‐ADRDA CERAD       Mixed   9
  Zuo            2006   European‐Americans   Caucasian   286    --        --                          36.7%              197   --      44.2%   NINCDS‐ADRDA             Mixed   8
  Mateo          2006   Spain                Caucasian   139    75.7      72.1                        33%                235   80.4    30%     NINCDS‐ADRDA             LOAD    11
  Wang           2008   Chinese              Asian       207    77.6      --                          48%                222   72.3    61%     NINCDS‐ADRDA             LOAD    5
  Lin            2008   Chinese              Asian       280    79.72     75.75                       24.6%              220   78.49   28.2%   NINCDS‐ADRDA DSM‐IV      LOAD    8
  Lorenzi        2010   Italian              Caucasian   164    75.49     71.63                       28.7%              54    66.79   51.9%   NINCDS‐ADRDA             Mixed   7

USA: United states of America; NINCDS: the National Institute of Neurological Disorders and Stoke; ADRDA: Alzheimer Diseases and Related Disorders Association; CERAD: the Consortium to Establish a Registry for Alzheimer\'s Disease; NIA‐Reagan: the National Institute on Aging and the Reagan Institute; DSM: the Diagnostic and Statistical Manual of Mental Disorders; AD: Alzheimer\'s disease; LOAD: late‐onset Alzheimer\'s disease; QS: quality score.

Number.

Age at examination.

Age at onset of Alzheimer\'s disease.

Percentage of male.
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###### 

Genotype and allele distribution of saitohin Q7R polymorphism among AD cases and controls in the included studies

  First author, year   Cases   Controls   HWE[a](#jcmm13079-note-0007){ref-type="fn"}                                                
  -------------------- ------- ---------- --------------------------------------------- ------ ----- ----- ----- ---- -------- ----- -------
  Conrad, 2002         26      17         8                                             69     33    22    8     0    52       8     0.399
  Verpillat, 2002      272     189        38                                            733    265   222   161   19   605      199   0.132
  Cook, 2002           119     73         11                                            311    95    190   104   15   484      134   0.874
  Streffer, 2003       144     68         13                                            356    94    84    56    4    224      64    0.134
  Pepłon′ska, 2003     76      23         1                                             175    25    74    23    3    171      29    0.469
  Oliveira, 2003       570     287        46                                            1427   379   189   110   21   488      152   0.362
  Clark‐1, 2003        97      33         5                                             227    43    226   97    17   549      131   0.127
  Clark‐2, 2003        57      8          0                                             122    8     106   12    0    224      12    0.561
  Combarros, 2003      177     109        29                                            463    167   170   120   17   460      154   0.482
  Tanahashi, 2004      15      0          0                                             30     0     15    0     0    30       0     NR
  Seripa‐1, 2004       70      41         6                                             181    53    71    26    2    168      30    0.831
  Seripa‐2, 2004       66      56         8                                             188    72    357   230   46   944      322   0.290
  Conrad, 2004         111     36         8                                             258    52    24    14    3    62       20    0.635
  Johansson, 2005      303     89         6                                             695    101   132   50    4    314      58    0.771
  Zuo, 2006            --      --         --                                            439    133   --    --    --   313      81    NR
  Mateo, 2006          121     18         --                                            --     221   14    --         0.79           
  Wang, 2008           207     0          0                                             414    0     222   0     0    444      0     NR
  Lin, 2008            279     1          0                                             559    0     220   0     0    440      0     NR
  Lorenzi, 2010        105     59         --                                            --     28    26    --    --   \>0.05         

AD: Alzheimer\'s disease; HWE: Hardy--Weinberg equilibrium; NR: not reported.

*P* value for HWE test in controls.
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Quantitative synthesis {#jcmm13079-sec-0011}
----------------------

The results of the overall meta‐analysis suggested that the Q7R polymorphism was significantly associated with an increased risk of AD in recessive model (RR *versus* QQ+QR, OR = 1.27, 95% CI = 1.01--1.60, *P* = 0.040; Fig. [2](#jcmm13079-fig-0002){ref-type="fig"}). Due to the limited number of studies, we could not stratify by ethnicity (three studies in Asians and one in African) [8](#jcmm13079-bib-0008){ref-type="ref"}, [9](#jcmm13079-bib-0009){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}, but after excluding the four studies not carried out in caucasians, the overall association was unchanged in all comparison models (Table [3](#jcmm13079-tbl-0003){ref-type="table-wrap"}). When stratified by the time of AD onset, we found the association between Q7R polymorphism and AD susceptibility was only significant in LOAD in RR *versus* QQ+QR model (OR = 1.56, 95% CI = 1.07--2.26, *P* = 0.021; Table [3](#jcmm13079-tbl-0003){ref-type="table-wrap"}). A similar situation was also found in subgroup analysis stratified by the quality of included studies, where in the recessive model, the Q7R polymorphism was significantly related to AD risk only in studies with high quality (OR = 1.37, 95% CI = 1.01--1.86, *P* = 0.043), while a null result was reported in studies with low quality in all genetic models (Table [3](#jcmm13079-tbl-0003){ref-type="table-wrap"}).

![Forest plots of saitohin Q7R polymorphisms and Alzheimer\'s disease\'s risk in RR *versus* QQ+QR model (fixed‐effects model). (OR = 1.27, 95% CI = 1.01--1.60, *P* = 0.040).](JCMM-21-1448-g002){#jcmm13079-fig-0002}

###### 

Meta‐analysis and heterogeneity test of the saitohin Q7R polymorphism and Alzheimer\'s disease

  Subgroups          Allele model (R *versus* Q)   Dominant model (RR+QR *versus* QQ)   Recessive model (RR *versus* QQ+QR)   Homozygous model (RR *versus* QQ)   Heterozygous model (QR *versus* QQ)                                                                                                                                                            
  ------------------ ----------------------------- ------------------------------------ ------------------------------------- ----------------------------------- ------------------------------------- ------- ------ ------- -------------------------- ----------- ------ ------- ------------------ ------- ------ ------- ------------------ ------- ------ -------
  Total              1.02(0.90--1.15)              0.761                                37.7                                  0.069                               0.95(0.85--1.06)                      0.390   29.2   0.137   **1.27(1.01**--**1.60)**   **0.040**   30.3   0.142   1.17(0.92--1.50)   0.206   24.3   0.205   0.94(0.84--1.06)   0.330   9.4    0.349
  Caucasian          1.02(0.90--1.15)              0.814                                45.5                                  0.037                               0.95(0.82--1.10)                      0.475   37.4   0.085   **1.27(1.01**--**1.60)**   **0.040**   30.3   0.142   1.17(0.92--1.50)   0.206   24.3   0.205   0.94(0.84--1.06)   0.290   19.8   0.250
  Time of AD onset                                                                                                                                                                                                                                                                                                                                               
  EOAD               1.00(0.81--1.23)              0.985                                0.0                                   0.812                               0.91(0.71--1.18)                      0.478   0.0    0.974   1.47(0.86--2.52)           0.164       0.0    0.517   1.37(0.79--2.38)   0.263   0.0    0.545   0.86(0.66--1.12)   0.254   0.0    0.960
  LOAD               1.09(0.92--1.29)              0.315                                0.0                                   0.663                               1.07(0.87--1.31)                      0.543   0.0    0.759   **1.56(1.07--2.26)**       **0.021**   19.6   0.290   1.34(0.85--2.09)   0.205   10.5   0.340   1.03(0.83--1.23)   0.779   0.0    0.795
  Quality score                                                                                                                                                                                                                                                                                                                                                  
  High               1.01(0.88--1.14)              0.933                                42.0                                  0.142                               0.96(0.82--1.12)                      0.597   37.3   0.172   **1.37(1.01--1.86)**       **0.043**   42.4   0.123   1.19(0.85--1.67)   0.317   34.0   0.194   0.93(0.79--1.10)   0.385   33.5   0.198
  Low                1.01(0.84--1.21)              0.939                                42.1                                  0.077                               0.95(0.81--1.10)                      0.493   32.8   0.146   1.15(0.81--1.64)           0.433       23.5   0.250   1.15(0.80--1.66)   0.436   28.7   0.209   0.96(0.81--1.13)   0.612   3.4    0.407

AD: Alzheimer\'s disease; EOAD: early‐onset Alzheimer\'s disease; LOAD: late‐onset Alzheimer\'s disease; OR: odds ratio; CI: confidence intervals.

John Wiley & Sons, Ltd

Heterogeneity analysis {#jcmm13079-sec-0012}
----------------------

For Q7R polymorphism, there was heterogeneity in R *versus* Q model when all eligible studies were included into meta‐analysis (*I* ^2^ = 37.7%, *P* ~Q~ = 0.069; Table [3](#jcmm13079-tbl-0003){ref-type="table-wrap"}). Galbraith plot analysis indicated that Conrad *et al*. (2002) was the outlier and main contributor to heterogeneity in R *versus* Q model (Fig. [3](#jcmm13079-fig-0003){ref-type="fig"}) [3](#jcmm13079-bib-0003){ref-type="ref"}. When omitting the outlier study, the insignificance of the OR was not altered but heterogeneity decreased (*I* ^2^ = 17.4%, *P* ~Q~ = 0.264). After excluding the four studies not conducted in caucasians [8](#jcmm13079-bib-0008){ref-type="ref"}, [9](#jcmm13079-bib-0009){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}, between‐study heterogeneities were detected under R *versus* Q model (*I* ^2^ = 45.5%, *P* ~Q~ = 0.037) and RR+QR *versus* QQ model (*I* ^2^ = 37.4%, *P* ~Q~ = 0.085; Table [3](#jcmm13079-tbl-0003){ref-type="table-wrap"}). After stratifying by the time of AD onset, the heterogeneity disappeared \[*I* ^2^ = 0.0% for all genetic models for both EOAD and LOAD, except for recessive model and homozygous model in LOAD (*I* ^2^ = 19.6%, *P* ~Q~ = 0.290; *I* ^2^ = 10.5%, *P* ~Q~ = 0.340, respectively)\] (Table [3](#jcmm13079-tbl-0003){ref-type="table-wrap"}). When subgroup analyses were performed in all comparison models, obvious significant heterogeneities were still observed in studies with low quality after stratified according to the quality score of included studies (R *versus* Q: *I* ^2^ = 42.1%, *P* ~Q~ = 0.077; Table [3](#jcmm13079-tbl-0003){ref-type="table-wrap"}).

![Galbraith plot of Saitohin Q7R polymorphism and Alzheimer\'s disease risk. The study by Conrad et al was the outlier in R *versus* Q model in the overall analysis.](JCMM-21-1448-g003){#jcmm13079-fig-0003}

Sensitivity analysis and bias diagnosis {#jcmm13079-sec-0013}
---------------------------------------

As the HWE of the control group in four studies was not reported, sensitivity analyses were performed by omitting one study each time [9](#jcmm13079-bib-0009){ref-type="ref"}, [12](#jcmm13079-bib-0012){ref-type="ref"}, [14](#jcmm13079-bib-0014){ref-type="ref"}, [15](#jcmm13079-bib-0015){ref-type="ref"}. The significances of ORs were not changed through the exclusion of any single study in all comparison models (data not shown). Funnel plot and Egger\'s test were conducted to assess possible publication bias. Ultimately, both funnel plot and Egger\'s test indicated no evidence of publication bias (Fig. [4](#jcmm13079-fig-0004){ref-type="fig"}).

![Funnel plot analysis and Egger\'s test of Q7R polymorphism and Alzheimer\'s disease risk. Each point represents a separate study for the indicated association. Funnel plot for contrast RR *versus* QQ+QR in the overall analysis (*P* = 0.984).](JCMM-21-1448-g004){#jcmm13079-fig-0004}

Discussion {#jcmm13079-sec-0014}
==========

AD is a complex disorder with multiple genetic and environmental factors that may have influences on disease susceptibility. However, the aetiology and pathogenesis of AD are not fully understood. To date, many researchers have reported the association of AD with gene polymorphism, among which APP, PSEN1, PSEN2 and APOE gene are widely accepted as important risk factors in AD. The association between STH Q7R polymorphism and AD has been investigated for many years, but the results remain controversial. As the single studies may have inadequate statistical power, here we performed a meta‐analysis known as an important tool to precisely evaluate the relationship between Q7R polymorphism and the risk of AD. We included 4387 cases and 3972 controls in this article. Meta‐analysis showed that the RR genotype of STH Q7R polymorphism was associated with an increased risk for AD. Subgroup analysis indicated that RR genotype of STH Q7R polymorphism leads to the increased risk of LOAD, but not EOAD. When stratified by the quality score of included studies, the RR genotype was found contributing to the increased risk of AD only in high‐quality studies.

The special localization of STH gene in a functionally critical position of the tau gene could explain its role in tauopathies. As STH locates in the intron between exons 9 and 10 of tau, there is a possibility that STH Q7R polymorphism may mediate the different expressions of tau isoforms through influencing alternative splicing of exon 10 [25](#jcmm13079-bib-0025){ref-type="ref"}. Alternative splicing of exon 10 defines two functionally different isoforms with either four repeats (4R) or three repeats (3R) depending on whether exon 10 is included or not [26](#jcmm13079-bib-0026){ref-type="ref"}. In normal adult human brains, the level of 3R isoforms is approximately equal to that of 4R isoforms [27](#jcmm13079-bib-0027){ref-type="ref"}. It was shown that 4R tau has a threefold binding affinity to tubulin than 3R tau and assembles microtubules more effectively as compared to 3R tau. The 4R‐to‐3R ratio appears to be essential for preventing neurodegeneration. Additionally, the Q7R polymorphism was in complete linkage disequilibrium with two extended tau haplotypes: The Q allele is located on the H1 tau haplotype, and the R allele is located on the H2 tau haplotype, respectively [21](#jcmm13079-bib-0021){ref-type="ref"}. With comparison to H1 tau haplotype carriers among frontotemporal lobar degeneration (FTLD) patients, H2 tau haplotype carriers had hypoperfusion of frontal medial and cingulated cortex [28](#jcmm13079-bib-0028){ref-type="ref"} and higher cerebrospinal fluid total tau and phospho tau [29](#jcmm13079-bib-0029){ref-type="ref"}. Evidence from population‐based studies also showed that the H2 MAPT haplotype was associated with FTLD and AD [30](#jcmm13079-bib-0030){ref-type="ref"}, [31](#jcmm13079-bib-0031){ref-type="ref"}, [32](#jcmm13079-bib-0032){ref-type="ref"}.

Between‐study heterogeneity is very common in meta‐analyses for genetic association studies, and it is necessary to find out the potential sources. Our meta‐analysis also showed significant heterogeneity in allele model in the overall effects. Galbraith plot analysis indicated that Conrad *et al*.\'s (2002) study was the outlier. Conrad *et al*.\'s (2002) study was first to report the association between Q7R polymorphism and AD risk with 51 cases and 30 controls. Due to the small number of subjects, result from this study was not convincing and may have potential bias. Furthermore, subgroup analyses were performed to explore the sources of heterogeneity and the stability of the result. Age is a very important factor for AD development, and most of AD is diagnosed in people over 65 years. Results from the stratification by the time of AD onset showed that AD risk was associated with late onset in recessive model, which indicated that the STH Q7R polymorphism may be age‐dependently associated with AD susceptibility. Possible explanation for the age‐dependent association could be the difference in circulating C‐reactive protein (CRP) level, a well‐known inflammatory biomarker involved in the pathogenesis of AD [33](#jcmm13079-bib-0033){ref-type="ref"}, [34](#jcmm13079-bib-0034){ref-type="ref"}. Previous research demonstrated that CRP level was significantly higher in LOAD than EOAD [35](#jcmm13079-bib-0035){ref-type="ref"}. When stratified by the quality score of included study, between‐study heterogeneity was found only in studies with low quality, suggesting that the differences of individual study\'s quality may be the potential confounder. Moreover, AD is such a multi‐factorial disease in relation to many gene variants and environmental factors that other genetic and environmental variables, as well as their possible interaction, may be potential contributors.

The association of STH gene polymorphism with AD risk has been evaluated by a previous meta‐analysis with six studies included [5](#jcmm13079-bib-0005){ref-type="ref"}. The results suggested that the RR genotype had a highly significant trend towards overrepresentation in AD compared with normal control subjects; however, the R allele was not significantly overexpressed in AD subjects. What\'s more, the meta‐analysis failed to include all eligible studies, and heterogeneity test and sensitivity analysis were not applied to this. In the present meta‐analysis of data from 19 case--control studies, we also found a notable increase in risk of AD and Q7R polymorphism. Additionally, we noticed this association only significantly existed in LOAD subjects, as well as in studies with high quality, whereas the small number of included studies in the earlier work limited the stratification.

To our knowledge, STH is an evolutionary locus that separates humans and their closest relatives from other mammals. The Q allele is remarkably common in humans; however, all nonhuman primates are homozygous for the R allele, which makes the Q allele a human‐specific marker and can be inferred to be most implicated in Alzheimer pathogenesis [36](#jcmm13079-bib-0036){ref-type="ref"}. Nevertheless, similar to previous meta‐analyses, there were also several limitations in the current study. First, the sample size of most eligible studies is relatively small and we had no ability to confirm whether studies included in our meta‐analysis had sufficient genetic power. Meanwhile, the results are not currently available from the Alzheimer Genome sequencing project, which includes more than 5000 patients and controls to strengthen the population genotype statistics. Second, we only included studies in English and might lead to language bias. According to Pan *et al*. (2005), the influence of language bias on meta‐analyses of observational studies may be as large as or even larger than its influence on randomized evidence [37](#jcmm13079-bib-0037){ref-type="ref"}. Third, the overall results of our study were derived from crude ORs due to lack of the original data, such as age, gender, ethnicity, education level and APOE ε4 status. Fourth, publication bias may exist because of no attempt to obtain unpublished studies, although both funnel plot and Egger\'s test indicated no evidence. In addition, current limited knowledge of STH structure--function relationships and clinical features are non‐negligible issues that do unfortunately weaken our results.

In conclusion, our meta‐analysis suggests that the RR genotype of STH Q7R polymorphism may be associated with an increased risk for AD, especially in caucasian population, late‐onset AD subjects and studies with high quality. Considering the limitations mentioned above, further well‐designed epidemiological studies with larger sample size and structure--function relationships should be conducted to confirm our findings.
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